Date Time
Molecular Imaging Determines Effectiveness of Novel Metastatic Breast Cancer Treatment
Reston, VA-Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy. According to research published in the February issue of The Journal of Nuclear Medicine, positron emission tomography (PET) imaging using an imaging agent called
18F-fluoroestradiol can help to determine which patients could benefit from treatments that could spare them from unnecessary chemotherapy.
Nearly two-thirds of invasive breast cancers are ER-positive, and endocrine therapy is the mainstay of treatment for these tumors because of its favorable toxicity profile and efficacy. Should cancer progress in these patients, however, salvage endocrine therapy with molecularly targeted agents or chemotherapy can help.
Global Proteomics Partnering Terms and Agreements Analysis Report 2020
News provided by
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter Proteomics partnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors Proteomics technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
As more Covid-19 vaccines become available in the U.S., it is getting tougher to run large clinical trials to test a new vaccine's ability to prevent disease because people are less willing to take a placebo forcing drugmakers and researchers to look for workarounds as they vet the next generation of shots and test new uses for authorized ones.
POLITICO
Get the Prescription Pulse newsletter
Email
Sign Up
By signing up you agree to receive email newsletters or updates from POLITICO and you agree to our privacy policy and terms of service. You can unsubscribe at any time and you can contact us here. This sign-up form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Presented by Gilead Sciences, Inc.
With David Lim, Susannah Luthi, Brianna Ehley and Emily Martin
On Tap
with House moves to install new policies The U.S. is still behind on pandemic response
as today looks eerily like 2020.
For the World Health Organisation, its fact-finding mission to China left many questions on the possible origins of the pandemic. In Beijing, however, the outcome was framed Thursday as something solid: vindication and triumph. The WHO s headline announcement, that it would rule out the possibility the virus accidentally leaked from a Wuhan lab, was hailed by Chinese officials and in state media as effectively silencing claims that China was hiding secrets and trying to deflect blame.
Ng Han Guan/AP
Thea Fischer of the World Health Organisation team speaks to journalists outside after a WHO-China Joint Study Press Conference held at the end of the WHO mission in Wuhan, China.